Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind Randomized Phase 2.5 Trial of ONY-P1 Vaccine Versus Placebo in Men With D0 Prostate Cancer Following Limited Androgen Ablation

NCT00514072 is registered in ClinicalTrials.gov with Kael-GemVax Co., Ltd. as lead sponsor.

NCT NCT00514072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00514072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind Randomized Phase 2.5 Trial of ONY-P1 Vaccine Versus Placebo in Men With D0 Prostate Cancer Following Limited Androgen Ablation
Lead sponsor
Kael-GemVax Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2007
Completion date
Not reported
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer